News | Artificial Intelligence | May 07, 2020

TeraRecon Launches Lung Density Analysis II

These solutions, the Lung Density Analysis II (LDA-II) workflow for Intuition and the Emergency Lung AI Suite, provide two deployment options for rapid access to lung segmentation and quantification tools that can be applied to a wide range of lung illnesses and have been optimized to adapt to the latest disease presentation states

May 7, 2020 — As COVID-19 makes its way across the globe, our customers are urgently connecting with us to share cases, ideas, and needs. TeraRecon responded by diverting the majority of our engineering and clinical resources to develop and release two innovative and practical solutions in just over three weeks. TeraRecon designed the solutions to address the urgent crisis as well as a much broader view of our customers’ needs—to deliver lasting value as an integrated part of any customers’ lung program or enterprise artificial intelligence (AI) roll-out. We are committed helping our customers leverage technology to extend the reach and responsiveness of care.

These solutions, the Lung Density Analysis II (LDA-II) workflow for Intuition and the Emergency Lung AI Suite, provide two deployment options for rapid access to lung segmentation and quantification tools that can be applied to a wide range of lung illnesses and have been optimized to adapt to the latest disease presentation states. 

Lung Density Analysis II (LDA-II) for Intuition

The newly released LDA-II allows TeraRecon Intuition customers to upgrade their advanced visualization systems with a custom lung workflow. By leveraging Intuition's capabilities in lung segmentation, volumetric histogram analysis, and automation, physicians quickly receive colorized densities and lung composition values that can be analyzed and quantified with little to no manual editing required.  LDA-II is available as a remotely installed upgrade to Intuition customers or comes included as standard functionality with a subscription to TeraRecon’s new AI-ready Intuition Titanium Suite.

Emergency Lung AI Suite

The newly released Emergency Lung AI Suite provides fast access to lung density analysis tools across the enterprise and securely extends access to physicians working remotely. This cloud-based rapid response platform allows physicians to upload cases, anonymize patient data, process the LDA-II algorithm, and receive notification of results regardless of where they are located. Whether in the emergency department, radiology, pulmonology, or at home, this pure cloud offering requires no installation and may be integrated to diagnostic and point-of-care solutions in minutes. The Emergency Lung AI Suite is extensible to other clinical use cases within a health system’s imaging and crisis readiness infrastructure.

For more information: www.terarecon.com

Related Content

The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
An interview with Eric Liederman, M.D., MPH, Director of Medical Informatics for The Permanente Medical Group, in Kaiser Permanente’s Northern California Region, on the explosion of telemedicine in the COVID-19 era

Getty Images

Feature | Radiology Business | January 20, 2021 | By Melinda Taschetta-Millane
More complex, longer interventional procedures such as structural heart interventions or this revascularization of a coronary chronic total occlusion (CTO) at Henry Ford Hospital in Detroit, requires angiography imaging systems that have improved image detail and lower radiation dose. However, purchase of new systems was put on hold by many hospitals in 2020 due to the sudden drop in elective procedures and diversion of resources due to the COVID-19. Photo by Dave Fornell.

More complex, longer interventional procedures such as structural heart interventions or this revascularization of a coronary chronic total occlusion (CTO) at Henry Ford Hospital in Detroit, requires angiography imaging systems that have improved image detail and lower radiation dose. However, purchase of new systems was put on hold by many hospitals in 2020 due to the sudden drop in elective procedures and diversion of resources due to the COVID-19. Photo by Dave Fornell.

Feature | Angiography | January 19, 2021 | By Bhvita Jani
January 19, 2021 – With the postponement of non-essential elective surgeries and medical procedures in 2020 to conser
AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s flagship image analysis platform.
News | Artificial Intelligence | January 18, 2021
January 18, 2021 — AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient ca
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images

News | Coronavirus (COVID-19) | January 08, 2021
January 8, 2021 — The U.S.